ESMO 2023 Archives - MediaMedic

ESMO China Voice | Professor Bin Shao : Comprehensive Genomic Analysis of Advanced HR+/HER2- Breast Cancer Patients Using Liquid Biopsy

By Mourabit Halima 2024.02.23

HR+/HER2- is the most common subtype of breast cancer, accounting for approximately 65% to 70% of all breast cancer cases. Improving the survival benefits for patients with advanced HR+/HER2- breast cancer has always been a hot topic in this field and a unanimous goal for scholars and experts. Exploring the genomic characteristics of advanced HR+/HER2- breast cancer can enhance our understanding of it, and even identify potential biomarkers that affect its treatment and prognosis. The team led by Professor Li Huiping from the Peking University Cancer Hospital conducted a comprehensive genomic analysis of advanced HR+/HER2- breast cancer patients using liquid biopsy technology. Their research results were included as a poster (abstract number: 496P) at this year's ESMO conference. Oncology Frontier has specially invited Professor Shao Bin to introduce the latest results of this study.

ESMO 2023丨Andrea Nccchi: Novel Intravesical Drug Delivery System Helps Bladder Cancer Patients Preserve Bladder, Reduce Risk of Recurrence

By El Bachir MOURABIT 2024.02.18

At the 2023 European Society of Medical Oncology (ESMO 2023), Dr. Andrea Nccchi reported a phase 2b clinical study at the mini oral presentation, using a new intravesical local chemotherapy delivery system. TAR200 is expected to become a treatment method for patients with high-risk non-muscle invasive bladder (HR MIBC) to reduce disease recurrence. In addition, ESMO 2023 also reported TAR201 and EV-302 study. Dr. Andrea Nccchi shared his views on these latest studies in an interview with " Oncology Frontier ".

ESMO 5-Minute Insights | DXd ADCs Shine at ESMO: Professor Jian Zhang Introduces Research in the Field of Breast Cancer

By Peter W. PENG 2023.11.28

ADC drugs, also known as Antibody-Drug Conjugates, combine targeted antibodies with cytotoxic drugs to accurately attack tumor cells and minimize damage to normal cells. In recent years, ADC drugs have made significant breakthroughs in the field of cancer treatment and have become a focus of attention. At this year's ESMO conference, several studies on ADC drugs garnered significant attention. In this report, Professor Jian Zhang from Fudan University-affiliated Cancer Hospital introduces the progress in the treatment of breast cancer using ADC drugs.

ESMO Hot Topic | Professor Han Liang : Phase III MATTERHORN Study on the Verge of Success, Significant Improvement in pCR with Neoadjuvant Durvalumab for Gastric Cancer

By Peter W. PENG 2023.11.17

The 2023 ESMO Annual Meeting took place from October 20th to 24th in Madrid, Spain. As a highly authoritative annual event in the field of oncology, it unveils cutting-edge advancements in cancer research each year. In the gastric cancer domain this year, the global Phase III MATTERHORN study on the anti-PD-L1 monoclonal antibody durvalumab was presented as a Late-breaking Abstract (LBA) with mid-term analysis results (Abstract No: LBA73). The interim analysis revealed a clinically and statistically significant increase in the pathologic complete response (pCR) rate with the neoadjuvant treatment regimen of durvalumab in combination with FLOT. The MATTERHORN study holds promise as the first positive neoadjuvant Phase III immunotherapy regimen for gastric cancer. "Oncology Frontier" is pleased to invite Professor Han Liang from Tianjin Medical University Cancer Institute to provide an in-depth interpretation of this study.

ESMO Exclusive Interview | Professor Changsong Qi: CAR-T Therapy IM96 Shows Significant Antitumor Activity in Advanced Colorectal Cancer with GCC Expression

By Peter W. PENG 2023.11.17

The 2023 European Society for Medical Oncology (ESMO) Annual Meeting took place in Madrid, Spain, from October 20th to 24th. The Oncology Frontier team delved into the frontline, capturing international advancements and witnessing the strides made by China in the global oncology arena. Professor Changsong Qi from Peking University Cancer Hospital delivered a crucial oral presentation (Abstract No: 1018O) at this conference. In an exclusive interview with Oncology Frontier, Professor Qi shared insights from his reported research and thoughts on colorectal cancer studies presented at this year's ESMO. This article compiles relevant content for readers.

ESMO 2023 | Dr. Silvia Stacchiotti: Advancements and Challenges in Treating Metastatic Sarcoma

By Peter W. PENG 2023.11.13

Metastatic sarcoma presents a formidable challenge in the realm of cancer treatment. The sheer diversity of sarcoma subtypes and the necessity of tailoring treatments to each specific histology makes the quest for effective therapies all the more complex. In this article, we delve deeper into the current landscape of advancements and challenges in the treatment of metastatic sarcoma, guided by the insights of Professor Stacchiotti.

ESMO 2023 | Dr. Andrea Necchi: Advancements in Intravesical Delivery Systems for the Treatment of Bladder Cancer

By Peter W. PENG 2023.11.13

Bladder cancer presents a complex challenge that demands innovative approaches to treatment. In recent years, significant progress has been made in the development of intravesical delivery systems for targeted therapy in bladder cancer patients. This article aims to provide a comprehensive overview of the latest advancements in intravesical delivery systems, with a particular focus on the TAR200 and TAR21210 systems. The application of intravesical delivery systems holds profound clinical significance in the treatment of bladder cancer. These systems provide a continuous and controlled exposure of the tumor to therapeutic agents, significantly enhancing the likelihood of successful treatment outcomes. Moreover, intravesical delivery systems offer a valuable alternative to radical cystectomy, a surgical procedure that certain patients may decline or be medically unfit for. The ultimate goal is to preserve the bladder while achieving a cure and preventing disease progression

ESMO 2023 | Dr. Ryan J. Sullivan: When does targeted therapy outperform immunotherapy in patients with advanced melanoma?

By Peter W. PENG 2023.11.13

The landscape of advanced melanoma treatment has witnessed a remarkable transformation with the introduction of targeted therapies and immunotherapies. While immunotherapy has shown great promise in various cancer types, there exist specific scenarios where targeted therapy can outshine immunotherapy. In this article, we delve into the situations where targeted therapy may be the preferred choice for advanced melanoma patients, while also examining the comparative efficacy and potential side effects of these treatment approaches.

ESMO 2023 | Dr. Henrik Grönberg: Outcome Adaptive Design and Biomarker-Based Treatment Selection

By Peter W. PENG 2023.11.06

Prostate cancer remains a significant global health concern, predominantly affecting men. In recent groundbreaking research led by Dr. Henrik Grönberg, a novel approach known as outcome adaptive design was implemented to revolutionize the assessment of different drugs simultaneously. This innovative study design incorporated the dynamic adjustment of randomization probabilities based on individual patient outcomes, enabling the selection of the most suitable treatment for each person. Furthermore, the study harnessed the power of biomarkers, particularly circulating tumor DNA, to guide treatment selection, ultimately aiming to enhance patient outcomes and overall quality of life.

ESMO 2023 | Dr. Kjetil Boye: Emerging Therapeutic Strategies and Promising Drugs May Benefit Sarcoma Patients

By Peter W. PENG 2023.11.06

The field of sarcoma treatment is currently undergoing a remarkable transformation with the development of cutting-edge therapeutic strategies and promising drugs. This article aims to provide an in-depth overview of these emerging treatment options and highlight key findings from recent research, shedding light on the potential breakthroughs in sarcoma management.